跳至主要内容
临床试验/NCT01487499
NCT01487499终止3 期

Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer

University of Florida1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2011年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
4
试验地点
1
主要终点
Solid Tumor Growth After Completion of Interventional Bronchoscopies

研究概览

简要总结

This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions:

  1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage SCLC by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls
  2. to implement a prospective clinical trial to test the feasibility and efficacy as measured by tumor growth and survival rates of intralesional chemotherapy for patients with recurrent SCLC after standard treatment.

详细描述

Subjects will receive standard of care treatment for SCLC with added treatment of Cisplatin injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome measurements of tumor growth and survival will be compared to subjects receiving standard of care treatment only.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Competent adult English speaking subjects
  • With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis,
  • With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction,
  • With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin

排除标准

  • Subjects who do not meet the inclusion criteria
  • Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy

研究组 & 干预措施

patients with limited stage SCLC

Experimental

Subjects with limited stage SCLC treated sequentially with cisplatin.

干预措施: Cisplatin (Drug)

结局指标

主要结局

Solid Tumor Growth After Completion of Interventional Bronchoscopies

时间窗: 18 months

The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.

次要结局

  • Overall Survival(5 years)
  • Progression-free Survival(18 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验